--- title: "U.S. stock intraday update: Gelteq rises 11.64% with increased trading volume, no positive news driving intensified capital speculation" type: "News" locale: "en" url: "https://longbridge.com/en/news/289956426.md" description: "Gelteq rose 11.64%; Eli Lilly fell 0.26%, with a transaction volume of USD 1.229 billion; Johnson & Johnson fell 0.52%, with a transaction volume of USD 859 million; Merck fell 0.07%, with a transaction volume of USD 604 million; AstraZeneca rose 0.82%, with a market value of USD 277.2 billion" datetime: "2026-06-16T18:42:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289956426.md) - [en](https://longbridge.com/en/news/289956426.md) - [zh-HK](https://longbridge.com/zh-HK/news/289956426.md) --- # U.S. stock intraday update: Gelteq rises 11.64% with increased trading volume, no positive news driving intensified capital speculation **U.S. Stock Market Midday Update** Gelteq, up 11.64%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Eli Lilly down 0.26%, with increased trading volume. Based on recent key news: 1. On June 16, Eli Lilly acquired 4E Therapeutics to advance non-opioid treatment options for chronic pain. This move may enhance its competitiveness in the non-opioid market and drive stock price volatility. 2. On June 15, Eli Lilly announced it would halve its investment plan in Germany, originally planned to invest €2.3 billion. This move may affect its expansion strategy in the European market, attracting market attention. 3. On June 15, Barclays analyst Emily Field maintained a buy rating on Eli Lilly, setting a target price of $1,400. The analyst's positive rating may provide support for the stock price. The competition in the obesity drug market is fierce, with intensified price wars. Johnson & Johnson down 0.52%, with increased trading volume. Based on recent key news: 1. On June 15, Johnson & Johnson announced an investment of over $1 billion in Florida to enhance its vision business. This move is part of its $55 billion investment plan in the U.S., aimed at expanding production and distribution capabilities, driving stock price volatility. 2. On June 15, Johnson & Johnson's global ENCOMPASS study showed that psoriasis patients are more inclined towards oral treatments. This study result may affect market expectations for its new drug Icotyde, thereby impacting the stock price. 3. On June 17, Johnson & Johnson's CEO stated that the company will achieve sustainable growth through scientific innovation, particularly driven by the new drug Icotyde, which may have a positive impact on the stock price. Increased macroeconomic uncertainty necessitates vigilance against volatility risks. Merck down 0.07%, with increased trading volume. Based on recent key news: 1. On June 15, Merck announced that its long-acting monoclonal antibody, Clonidine Injection, received approval from the National Medical Products Administration of China for the prevention of RSV infections in newborns and infants. This approval may enhance market confidence in Merck's product line, despite a slight decline in stock price. 2. On June 16, Merck signed a multi-target drug discovery and licensing agreement worth up to $510 million with Protillion Biosciences. This collaboration may enhance Merck's competitiveness in drug development, attracting investor attention. 3. On June 16, sales of Merck's Gardasil vaccine declined in China and Japan, reflecting a trend of weak demand, which poses financial and market risks to the company's vaccine portfolio. Weak vaccine demand increases market risks. **Stocks with High Market Capitalization in the Industry** AstraZeneca rose by 0.82%. Based on recent key news: 1. On June 15, AstraZeneca's Ultomiris received priority review in the United States for the treatment of adult patients with immunoglobulin A nephropathy. This news drove the stock price up, reflecting market confidence in the drug's potential. Source: Reuters 2. On June 16, AstraZeneca and other pharmaceutical companies plan to invest $50 billion in the United States to expand manufacturing and R&D capabilities in response to tariff policies. This strategic investment enhances market expectations for AstraZeneca's future growth. Source: Reuters 3. On June 15, AstraZeneca's cancer drug Truqap received FDA approval for certain prostate cancer patients, marking another breakthrough for the company in innovative treatments. This approval further boosted investor confidence in the company's R&D capabilities. Source: Reuters The pharmaceutical industry is accelerating investment, with clear policy support ### Related Stocks - [GELS.US](https://longbridge.com/en/quote/GELS.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [AZN.US](https://longbridge.com/en/quote/AZN.US.md) ## Related News & Research - [Gelteq Limited Advances Clinical Programs and Asia Expansion in First Half of 2026](https://longbridge.com/en/news/291339548.md) - [Gelteq publishes MD&A for six months ended Dec. 31, 2025](https://longbridge.com/en/news/291337263.md) - [Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion | GELS Stock News](https://longbridge.com/en/news/288727770.md) - [Gelteq signs debt financing deal of up to US$3.5 million with institutional investor](https://longbridge.com/en/news/290053081.md)